Purevax FeLV
vaccine against feline leukaemia
Table of contents
Overview
Purevax FeLV is a veterinary vaccine used to treat feline leukaemia in cats. It contains the active substance recombinant live canarypox virus (vCP97).
Purevax FeLV is used to vaccinate cats from the age of eight weeks against feline leukaemia, an illness affecting the immune system caused by a type of virus known as a retrovirus. The vaccine is used to prevent the symptoms of the disease and to prevent FeLV from remaining in the blood.
Authorisation details
Product details | |
---|---|
Name |
Purevax FeLV
|
Agency product number |
EMEA/V/C/000056
|
Active substance |
feline leukaemia virus recombinant canarypox virus (vCP97)
|
International non-proprietary name (INN) or common name |
vaccine against feline leukaemia
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI06AD
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
10
|
Date of issue of marketing authorisation valid throughout the European Union |
13/04/2000
|
Contact address |
Product information
14/08/2020 Purevax FeLV - EMEA/V/C/000056 - IB-0028
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Immunologicals for felidae
Therapeutic indication
Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.
Onset of immunity has been demonstrated 2 weeks after primary vaccination course.
The duration of immunity is one year after the last vaccination.